ReviewInternational journal of molecular sciences2022
The Treatment of Advanced Melanoma: Therapeutic Update.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Hydrazones as Potential Antimelanoma Prototypes: A Systematic and Patent Review.Anti-cancer agents in medicinal chemistry · 2026Pooled it
- Autophagy in Melanoma: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Microneedle-based theranostics for melanoma: Advances and outlook.Materials today. Bio · 2026Review
- Diagnostic Challenge of Immune Checkpoint Inhibitor-Induced Hypophysitis in Patient With Melanoma.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026Article
- Mucosal melanoma: clinicopathological, molecular and prognostic features in a retrospective cohort.Virchows Archiv : an international journal of pathology · 2026Article
- TMT proteomics reveals that miR-425-5p promotes proliferation and metastasis of malignant melanoma by inhibiting SCARA5.Cancer cell international · 2026Article
- R-loop processing via REXO4-RNaseH1-mediated endo- and exo-cleavage coupling mode prevents genome instability and antitumor immunity.Science advances · 2026Article
- A dissolvable microneedle patch co-delivering Zerumbone and ICG for combined chemo-photothermal therapy of melanoma.Scientific reports · 2026Article
- The impact of β-glucan yeast extract treatment on melanoma development, tumor-cell deposit infiltration, and immune response.Frontiers in immunology · 2026Article
- Serum amyloid P component suppresses melanoma growth and metastasis by inhibiting CCL1 secretion from macrophages.American journal of cancer research · 2026Article
- Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.Journal for immunotherapy of cancer · 2025Article
- 3D bioprinted melanoma models: a novel paradigm for the assessment of anticancer strategies combining PDT and drug delivery systems.Biomedical engineering online · 2025Review
- MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy.Molecular cancer · 2025Review
- Overcoming impaired antigen presentation in tumor draining lymph nodes facilitates immunotherapy.bioRxiv : the preprint server for biology · 2025Article
- A Milestone in the Shift from "Passive Killing" to "Active Immunomodulation" in Cancer Treatment-Progress in Melanoma Vaccine Research.Current treatment options in oncology · 2025Review
- Addressing Immune Response Dysfunction in an Integrated Approach for Testing and Assessment for Non-Genotoxic Carcinogens in Humans: A Targeted Analysis.International journal of molecular sciences · 2025Review
- Let-7a microRNA modulates caspase-3-dependent apoptosis in melanoma cells treated with dabrafenib and trametinib combination.Irish journal of medical science · 2025Article
- Article
- Comprehensive systems biology analysis reveals splicing factor contributions to cutaneous melanoma progression.Scientific reports · 2025Article
- Tumor-Infiltrating Lymphocyte Cell Therapy for the Treatment of Advanced Melanoma: From Patient Identification to Posttreatment Management.Journal of the advanced practitioner in oncology · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma is the main cause of death for skin cancer. The majority of patients with a diagnosis of melanoma have localized disease, which can be successfully treated with surgical treatment. However, the surgical approach is not curative for advanced melanoma (AM). Indeed, the management of AM is still challenging, since melanoma is the solid tumor with the highest number of mutations and cancer cells have the capacity to evade the immune system. In the past, the treatment of AM relied on chemotherapeutic agents, without showing efficacy data. Recent knowledge on melanoma pathogenesis as well as the introduction of immunotherapies, targeted therapies vaccines, small molecules, and combination therapies has revolutionized AM management, showing promising results in terms of effectiveness and safety. The aim of this review is to assess and to discuss the role of emerging therapies for AM management in order to obtain a complete overview of the currently available treatment options and future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.